Holen Sie sich die Stockscreener-App
25.51
4.21%
-1.12
Handel nachbörslich:
25.51
Schlusskurs vom Vortag:
$26.63
Offen:
$26.56
24-Stunden-Volumen:
1.91M
Relative Volume:
2.21
Marktkapitalisierung:
$3.74B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-272.55M
KGV:
-13.22
EPS:
-1.93
Netto-Cashflow:
$-243.55M
1W Leistung:
-18.08%
1M Leistung:
-13.44%
6M Leistung:
-16.91%
1J Leistung:
-24.57%
1-Tages-Spanne:
$25.24
$27.00
1-Wochen-Bereich:
$25.24
$31.18
52-Wochen-Spanne:
$24.67
$45.58
Immunovant Inc Stock (IMVT) Company Profile
Firmenname
Immunovant Inc
Sektor
Branche
Telefon
917-580-3099
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Vergleichen Sie IMVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| IMVT | 25.51 | 3.74B | 0 | -272.55M | -243.55M | -1.93 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-13 | Hochstufung | UBS | Neutral → Buy |
| 2023-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Eingeleitet | BofA Securities | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2023-02-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-08-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-01 | Herabstufung | Stifel | Buy → Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-12 | Eingeleitet | Guggenheim | Buy |
| 2020-10-08 | Eingeleitet | Stifel | Buy |
| 2020-10-02 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
Principal Financial Group Inc. Purchases 391,436 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
(IMVT) Technical Data - Stock Traders Daily
FMR LLC's Strategic Acquisition of Immunovant Inc Shares - GuruFocus.com
Immunovant (NASDAQ:IMVT) Posts Earnings Results, Misses Expectations By $0.15 EPS - MarketBeat
Analysts Provide An Important Insights On Immunovant Inc (IMVT) - Stocks Register
Immunovant’s Strategic Advances in Autoimmune Therapies - TipRanks
Interesting IMVT Put And Call Options For March 2025 - Nasdaq
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus - Yahoo Finance
Immunovant's (IMVT) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Immunovant Inc (IMVT) Quarterly 10-Q Report - Quartzy
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 - The Manila Times
Immunovant Advances IMVT-1402 with 5 IND Clearances Despite Widening Losses | IMVT Stock News - StockTitan
Immunovant Breaks Above 200-Day Moving AverageBullish for IMVT - Nasdaq
Emerald Mutual Fund Advisers Trust Has $5.24 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Where are the Opportunities in (IMVT) - Stock Traders Daily
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Position Boosted by abrdn plc - MarketBeat
Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - MarketBeat
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - The Manila Times
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - ForexTV.com
Immunovant's chief medical officer sells $94,171 in stock By Investing.com - Investing.com Canada
Immunovant CTO Jay Stout sells $80,912 in stock By Investing.com - Investing.com Canada
Immunovant, Inc. (NASDAQ:IMVT) CTO Sells $80,912.20 in Stock - MarketBeat
Immunovant CTO Jay Stout sells $80,912 in stock - Investing.com India
Immunovant's chief medical officer sells $94,171 in stock - Investing.com India
Immunovant's chief legal officer Mark Levine sells shares worth $128,780 By Investing.com - Investing.com Australia
Immunovant's chief legal officer Mark Levine sells shares worth $128,780 - Investing.com
Immunovant CFO Eva Renee Barnett sells $94,172 in stock By Investing.com - Investing.com Australia
Immunovant's chief medical officer William Macias sells $91,782 in stock - Investing.com India
Immunovant's chief legal officer sells $82,339 in stock By Investing.com - Investing.com Australia
Immunovant's chief legal officer sells $82,339 in stock - Investing.com India
Exchange Traded Concepts LLC Buys 9,438 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant CFO Eva Renee Barnett sells $94,172 in stock - Investing.com
Immunovant CEO Peter Salzmann sells $261,845 in shares By Investing.com - Investing.com Australia
Immunovant CEO Peter Salzmann sells $261,845 in shares - Investing.com
Immunovant, Inc. (NASDAQ:IMVT) Insider Sells $91,782.52 in Stock - MarketBeat
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
IMVT (Immunovant Inc) has impressive results - US Post News
Raymond James gives an Outperform recommendation for Immunovant Inc (IMVT) - Knox Daily
Analyzing Ratios: Immunovant Inc (IMVT)’s Financial Story Unveiled - The Dwinnex
Immunovant: Switching Lead Candidates Increases Risk (NASDAQ:IMVT) - Seeking Alpha
The Manufacturers Life Insurance Company Decreases Stake in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Immunovant CEO sells over $131k in company stock By Investing.com - Investing.com Australia
Immunovant CFO sells over $150k in company stock By Investing.com - Investing.com Australia
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):